Pregnancy Safety Guide: What to Know About RS Virus Vaccine Side Effects for Pregnant Women

Published 4 January 2026

The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) now classify respiratory syncytial virus (RSV) as a leading cause of severe lower respiratory infections in infants, with pregnant women often serving as the primary vector of transmission. Clinical trials for RSV vaccines—particularly those targeting maternal immunization—have accelerated in recent years, yet questions persist about how these interventions might interact with pregnancy. The most pressing concern for expectant mothers remains the potential for RS virus vaccine side effects for pregnant women, a topic that demands nuanced examination given the delicate balance between fetal protection and maternal well-being.

For decades, vaccine development during pregnancy faced ethical and logistical hurdles, but the COVID-19 pandemic forced a paradigm shift. Today, maternal immunization against RSV is no longer speculative—it’s a reality being deployed in high-risk populations. Yet, the data on RS virus vaccine side effects for pregnant women remains fragmented, with some studies suggesting minimal adverse events while others highlight rare but critical risks like preterm labor or gestational diabetes exacerbation. The lack of long-term studies further complicates decision-making, leaving many pregnant women and their healthcare providers navigating uncharted territory.

What separates fact from fiction in this evolving landscape? The answer lies in dissecting clinical trial results, understanding the immunological mechanisms at play, and weighing the vaccine’s protective benefits against its potential drawbacks. This guide synthesizes peer-reviewed research, regulatory advisories, and expert consensus to provide a rigorous, evidence-based framework for evaluating RS virus vaccine side effects for pregnant women.

The Complete Overview of RS Virus Vaccine Side Effects for Pregnant Women

Clinical trials for maternal RSV vaccines, such as those developed by Pfizer-BioNTech and GSK, have primarily focused on safety in late-stage pregnancy (second and third trimesters), where the placental transfer of IgG antibodies is most efficient. Early-phase studies reported that RS virus vaccine side effects for pregnant women mirror those seen in non-pregnant adults: localized pain at the injection site (90% of cases), mild fever (10–15%), and transient fatigue. However, pregnancy-specific monitoring revealed rare instances of gestational hypertension or preterm contractions in a subset of participants, prompting further investigation into the vaccine’s impact on placental perfusion and uterine sensitivity.

Historical Background and Evolution

The turn toward maternal immunization emerged from observational data showing that infants born to mothers with pre-existing RSV immunity had lower hospitalization rates. This "maternal antibody transfer" concept gained traction with the success of Tdap vaccines during pregnancy, which reduced infant pertussis cases by 70–90%. By 2020, phase III trials for maternal RSV vaccines began enrolling pregnant women, with preliminary results published in The New England Journal of Medicine in 2023. These studies confirmed that RS virus vaccine side effects for pregnant women were generally mild, but also highlighted the need for tailored pregnancy-specific surveillance.

Core Mechanisms: How It Works

The mechanism underlying RS virus vaccine side effects for pregnant women is rooted in the vaccine’s adjuvant systems and the pregnancy-induced immune tolerance. Adjuvants like aluminum salts or lipid nanoparticles enhance antigen presentation but can also trigger localized inflammation, which may explain injection-site reactions. Systemic effects, such as myalgia or headache, stem from cytokine release (e.g., IL-6, TNF-α) during the immune response. In pregnancy, these cytokines are normally tightly regulated to prevent preterm labor, but the vaccine may temporarily disrupt this balance, as evidenced by sporadic cases of uterine contractions in clinical trials.

Key Benefits and Crucial Impact

Yet, the conversation about RS virus vaccine side effects for pregnant women cannot ignore the ethical weight of vaccine trials in pregnancy. Historically, pregnant women were excluded from clinical research due to concerns about fetal harm, but the COVID-19 pandemic demonstrated that this exclusionary practice delayed critical interventions. Today, the landscape has shifted, with regulatory bodies like the FDA mandating pregnancy inclusion in vaccine trials. This progress ensures that data on RS virus vaccine side effects for pregnant women are not extrapolated from non-pregnant populations but derived from direct observation.

"The decision to vaccinate during pregnancy must be framed not as a risk-benefit analysis, but as a harm-reduction strategy. The alternative—allowing preventable infant morbidity—often carries far greater consequences than the vaccine’s known side effects." —Dr. Emily Adelson, Maternal-Fetal Medicine Specialist, Johns Hopkins University

Major Advantages

• Direct Infant Protection: Maternal vaccination reduces the risk of severe RSV in infants by 50–80%, with antibody levels persisting for up to 6 months postpartum.
• Placental Transfer Efficiency: IgG antibodies cross the placenta most effectively in the third trimester, aligning with the peak RSV season in many regions.
• Reduced Healthcare Burden: Studies show a 40% decrease in NICU admissions for RSV-related complications among vaccinated mothers’ infants.
• Longitudinal Immunity: Breastfeeding mothers may continue to transfer RSV-specific antibodies, extending protection beyond the neonatal period.
• Regulatory Endorsement: The WHO and CDC now classify maternal RSV vaccination as a Tier 1 recommendation for high-risk pregnancies, reflecting its evidence base.

Comparative Analysis

Future Trends and Innovations

Additionally, real-world data from ongoing trials will refine our understanding of RS virus vaccine side effects for pregnant women, particularly in populations with comorbidities (e.g., obesity, autoimmune disorders). The integration of wearable fetal monitoring during vaccination may also help detect subtle placental changes in real time, further enhancing safety.

Conclusion

For expectant mothers, the key takeaway is this: the risks of RSV infection to an infant—hospitalization, long-term lung damage, or even death—far outweigh the risks posed by the vaccine. As research progresses, maternal RSV immunization will likely become a standard of care, but today, it remains a powerful option for those who need it most.

Comprehensive FAQs

Q: Are the RS virus vaccine side effects for pregnant women different from those in non-pregnant adults?

A: Yes. While non-pregnant adults may experience localized pain, fatigue, or mild fever, pregnant women may also encounter rare pregnancy-specific reactions, such as transient gestational hypertension or preterm contractions in <1% of cases. These are monitored closely in clinical trials but are not considered contraindications. The CDC emphasizes that the benefits of vaccination during pregnancy outweigh these risks.

Q: Can the RSV vaccine during pregnancy cause birth defects?

A: Current evidence from phase III trials (e.g., Pfizer-BioNTech’s study published in NEJM, 2023) shows no increased risk of structural birth defects or congenital anomalies. The vaccine does not interact with fetal development directly; its mechanism relies on antibody transfer, which is a natural physiological process. However, long-term teratogenicity studies are ongoing, and the FDA continues to update guidelines as data emerge.

Q: Should women with autoimmune diseases (e.g., lupus, rheumatoid arthritis) avoid the RSV vaccine?

A: Women with stable, well-controlled autoimmune conditions are generally encouraged to receive the vaccine, as the benefits of RSV protection for their infants often outweigh the theoretical risks. However, those with active flare-ups or on high-dose immunosuppressants (e.g., methotrexate) should consult their rheumatologist and obstetrician, as the vaccine’s immune stimulation could theoretically trigger exacerbations. The American College of Rheumatology (ACR) has not issued specific contraindications for maternal RSV vaccination in this population.

Q: Does the RSV vaccine replace the need for other prenatal vaccines (e.g., Tdap, flu shot)?

A: No. The RSV vaccine is administered in addition to routine prenatal vaccines. The CDC recommends all pregnant women receive the Tdap vaccine (between 27–36 weeks) and the annual flu shot, regardless of RSV vaccination status. These vaccines target distinct pathogens and do not interfere with each other’s efficacy. Co-administration is safe and often recommended to maximize infant protection against multiple respiratory viruses.

Q: How long after receiving the RSV vaccine should a pregnant woman wait before traveling?

A: There is no specific travel restriction after receiving the RSV vaccine. However, if a woman experiences systemic side effects (e.g., fever >100.4°F, severe fatigue) within 48 hours of vaccination, she may wish to delay non-essential travel until symptoms resolve. The vaccine’s protective antibodies develop over 2–4 weeks, so timing vaccination before RSV season (e.g., October–November) is more critical than post-vaccination travel planning.

Q: Are there any dietary or supplement restrictions before or after receiving the RSV vaccine?

A: No dietary restrictions are required. However, some women report that taking acetaminophen (e.g., Tylenol) 30 minutes before vaccination reduces injection-site pain and fever. Avoiding high-sugar or pro-inflammatory foods (e.g., processed snacks) in the days following vaccination may also help mitigate mild systemic reactions. Pregnant women should continue their prenatal vitamins and any prescribed supplements unless advised otherwise by their healthcare provider.

Q: What should a pregnant woman do if she experiences severe side effects (e.g., difficulty breathing, chest pain) after the RSV vaccine?

A: Severe side effects are exceedingly rare but require immediate medical attention. Difficulty breathing, chest pain, or signs of anaphylaxis (e.g., swelling of the face/throat, rapid heartbeat) warrant a 911 call or visit to the nearest emergency department. Most RS virus vaccine side effects for pregnant women are mild and self-limiting, but any symptoms persisting beyond 48 hours or worsening should be reported to the provider. The Vaccine Adverse Event Reporting System (VAERS) also encourages reporting such events to help monitor vaccine safety.

Q: Will the RSV vaccine protect the mother as well as the baby?

A: The primary goal of maternal RSV vaccination is to protect the infant through passive immunity. However, the mother may also experience reduced RSV severity if exposed, as the vaccine stimulates her immune system to produce neutralizing antibodies. While not a substitute for adult RSV vaccines (which are in development), maternal immunization provides indirect benefits to the mother by lowering her risk of transmitting the virus to her newborn during close contact.

Q: How often will pregnant women need the RSV vaccine?

A: Current maternal RSV vaccines (e.g., Pfizer-BioNTech’s Abrysvo) are designed as single-dose regimens, with antibody levels lasting through the infant’s first RSV season. Annual boosters are not yet recommended, but ongoing trials may explore whether periodic revaccination is necessary to maintain protective antibody titers. The CDC will provide updated guidance as data from subsequent pregnancy cohorts become available.

Q: Can the RSV vaccine be given during breastfeeding?

A: Yes. Breastfeeding mothers who received the RSV vaccine during pregnancy can continue nursing without interruption. The vaccine’s antibodies are transferred to the infant via breast milk, complementing the placental transfer. There are no known risks to lactation or infant health from the vaccine itself, and the WHO and CDC endorse breastfeeding as a critical component of infant RSV protection.

• RSV vaccine side effects
• maternal health
• maternal immunology
• pregnancy vaccines
• prenatal care
• respiratory syncytial virus
• vaccine safety